66th ASH Annual Meeting: ASH Poster Walk on Improving Access to Cell and Gene Therapies Hosted by Blood Global Hematology (For In-person Participants)

ASH Poster Walks

Research, Clinical trials, Clinical Practice (Health Services and Quality), Clinical Research, Health outcomes research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Health disparities research, Diversity, Equity, and Inclusion (DEI), Education, Gene Therapy, Real-world evidence, Treatment Considerations, Biological therapies

Halls G-H - Blood Journals Studio (San Diego Convention Center)

Novel cell and gene therapies have transformed the care of patients with hematologic disorders. Unfortunately, these life-saving therapies are not accessible to all patients who may benefit from them, both on a local and global scale.

This Poster Walk is meant to raise awareness about the challenges (both locally and internationally) of delivering cell and gene therapies to patients, highlight important research addressing these issues, and enhance discussions related to these topics. To that end the walk will highlight abstracts focusing on national and international disparities in access to cell and gene therapies, as well as abstracts highlighting how to make these therapies more accessible for patients (reducing cost, improving infrastructure, etc.).

Join us in the Blood Studio located in the main Poster Hall for this in-person poster walk hosted by ASH’s Blood Global Hematology journal.

5037

Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

Veit L. Buecklein, MD¹^*, Francis A. Ayuk, M.D.²^*, Tobias A.W. Holderried, MD³^*, Christine Mai, MD⁴^*, Bradley Kievit, MSc, MPH⁵^*, Rob Blisset, EngD⁵^*, Brett Doble, PhD⁶^*, Geoff Reid⁷^*, Laura Reimeir, MD⁸^*, Caroline Bruns, PhD⁸^* and Sachin Vadgama⁷^*

¹Department of Medicine III, LMU University Hospital, Munich, Germany
²Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
³Universitaetsklinikum Bonn (UKB), Bonn, Germany
⁴AplusA, Lyon, France
⁵Maple Health Group, LLC, New York, NY
⁶Kite, a Gilead Company, Santa Monica, CA
⁷Kite, A Gilead Company, Santa Monica, CA
⁸Gilead Sciences GmbH, Munich, Germany

3663

Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Brian Hoeynck, MD¹, Shakthi Bhaskar, MD², Andrew P Jallouk, MD, PhD³, Bhagirathbhai R. Dholaria, MBBS¹, Bipin N. Savani, MD², Olalekan O. Oluwole, MD, MPH, MBBS², David Morgan, MD²^*, Salyka M. Sengsayadeth, MD²^*, Adetola A. Kassim, MD, MBBS, MS¹ and Vivek Patel, MD²

¹Vanderbilt University Medical Center, Nashville, TN
²Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
³The University of Texas MD Anderson Cancer Center, Nashville, TN

5044

Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Marie Michele Sainvil, MD^1,2, Melissa Lowe, MS³^*, Delaney Underwood, MS⁴^*, Yan Li, PhD³^*, Tomi F. Akinyemiju, PhD, MS.^1,5^*, Taewoong Choi, MD^1,6, Cristina Gasparetto, MD^1,6^*, Mitchell Horwitz, MD^1,6, Gwynn D. Long, MD^1,6^*, Richard Lopez, MD^1,6^*, Stefanie Sarantopoulos, MD, PhD^1,6, Edwin Alyea III, MD^1,6^*, Nelson J. Chao, MD^1,6, Thomas W. LeBlanc, MD, MA, MS^1,5,6, Yubin Kang, MD^1,6, Suzanne Kirby, MD, PhD^1,6, Chenyu Lin, MD^1,6, Matthew Stuart McKinney, MD^1,6, Alexandra Stefanovic, MD^1,6, Jie Wang, MD, MS^1,6, Andrea Sitlinger, MD^1,6^*, Sendhilnathan Ramalingam, MD⁶, Anthony D. Sung, MD⁷ and Sanghee Hong, MD^1,6

¹Duke Cancer Institute, Duke University School of Medicine, Durham, NC
²Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, durham, NC
³Duke Cancer Institute Biostatistics Shared Resource, Duke University, Durham, NC
⁴Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham
⁵Department of Population Health Sciences, Duke University School of Medicine, Durham, NC
⁶Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
⁷Division of Hematologic Malignancies and Cellular Therapy, Kansas University, Kansas City, KS

1104

Small Activating RNA-Mediated Induction of HBG Via Liposome Delivery for In Vivo Treatment of Sickle Cell Disease and Beta-Thalassemia

Laura Sinigaglia, PhD¹^*, Marcella O'Reilly, PhD²^*, Rhea Bhalla, MSc³^*, Khoa Chung, PhD²^*, Pardis Piri Dizaji, MSc²^*, Victoria Begley, PhD⁴^*, Rose Hodgson, PhD²^*, Gabriela Lin, PhD²^*, Konstantinos Vanezis, PhD⁴^*, Julieta Tesone, PhD⁴^*, Helen Paterson, PhD⁴^*, Shreyasi Swamy, MSc²^*, Henrik Hansen, PhD⁵^*, Natalia Izotova, PhD⁶^*, Bruno Doreste, PhD⁶^*, Yulia Lomonosova, PhD⁷^*, Luke Haslett, PhD⁶^*, Robert Habib, MBA^8,9^*, Robert F Place, PhD⁷^*, Jon Voutila, PhD⁷^*, Vikash Reebye, PhD^8,10^*, Troels Koch, PhD⁶^* and Brid M Ryan, PhD⁷^*

¹Rare Genetic Diseases, MiNA Therapeutics Ltd, London, United Kingdom
²Rare Genetic Diseases, MiNA Therapeutics, London, United Kingdom
³Rare Genetic Diseases, MiNa Therapeutics, London, United Kingdom
⁴Rare Genetic Diseases, MiNA therapeutics, London, United Kingdom
⁵MiNA therapeutics, London, United Kingdom
⁶Rare Genetic Disease, MiNA therapeutics, London, United Kingdom
⁷Rare Genetic Disease, MiNA Therapeutics, London, United Kingdom
⁸Mina Therapeutics Ltd, London, United Kingdom
⁹Rare Genetic Disease, MiNA therapeutics, london, United Kingdom
¹⁰Imperial College London, London, United Kingdom

2197

Delivery of Gene Writers In Vivo to Hematopoietic Stem Cells and T Cells Using Targeted and Untargeted Lipid Nanoparticles (LNP)

Michael T. Monte, MS^*, Lorenzo Tozzi, PhD^*, Rahul Palchaudhuri, PhD^*, Apiwat Wangweerawong, PhD^*, Yaser Heshmati, PhD, Giulia Schiroli, PhD^*, Han Gu, PhD^*, Yu Cao, PhD^*, William E. Salomon, PhD^*, Anne Bothmer, PhD^*, Jason Rodriguez^*, Mohit Gupta, PhD^*, James B. Rottman, PhD, DVM^*, William Querbes, PhD^*, Cecilia Cotta-Ramusino, PhD^*, Michael C Holmes, PhD^*, Hari Pujar, PhD^* and Z. Jane Wang, PhD^*

Tessera Therapeutics, Somerville, MA

3634

From Theory to Therapy: Evaluating Canadian Hemophilia Treatment Centres' Readiness for Gene Therapy Implementation

Roy Khalife, MD, FRCPC^1,2, Lindsay Cowley, MA¹^*, Alan T. Tinmouth, MD, MSc^1,3^*, Lisa D. Duffett, MD, MSc^1,3^*, Vanessa Bourck, RN, BScN, MN⁴^*, Alfonso Iorio, MD, PhD⁵, Davide Matino, MD, MSc⁶^*, Kay Decker, RN⁷^*, Karen Strike, PhD, MScPT, BKinHons⁸^*, David Page⁹^*, Natasha Pardy, MD, FRCPC¹⁰^*, Jerome M. Teitel, MD¹¹ and Haowei Linda Sun, MD MHSc FRCPC¹²

¹Ottawa Hospital Research Institute, Ottawa, ON, Canada
²Department of Medicine, University of Ottawa, The Ottawa Hospital, Gatineau, QC, Canada
³Department of Medicine, University of Ottawa, Ottawa, ON, Canada
⁴The Ottawa Hospital, Ottawa, ON, Canada
⁵Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
⁶Thrombosis and Atherosclerosis Research Institute (TaARI), McMaster University, Hamilton, ON, Canada
⁷McMaster Children's Hospital, Hamilton Health Sciences, Hamilton, ON, Canada
⁸Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
⁹Canadian Hemophilia Society, Montreal, QC, Canada
¹⁰Division of Hematology, Eastern Health, St. John's, NF, Canada
¹¹Division of Hematology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada
¹²Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB, Canada

See more of: ASH Poster Walks

<< Previous Poster Walk Application | Next Poster Walk Application >>